Business Model & Revenue
Codexis operates as a technology platform company focused on enzymatic solutions for pharmaceutical manufacturing. The company's core offering is ECO Synthesis (Enzyme-Catalyzed Oligonucleotide Synthesis), a proprietary manufacturing platform for siRNA (small interfering RNA) therapeutics. Revenue is generated through three primary channels:
Product Sales (Heritage Biocatalysis): Codexis sells enzymes to pharmaceutical companies for small-molecule drug manufacturing. This business has stabilized at ~64% gross margins and supports 14 late-stage clinical programs. Two recent data readouts were positive, positioning the company for commercial approval activities.
Services Revenue (ECO Synthesis): Codexis provides feasibility studies, preclinical material manufacturing, and development services to biotech and pharma customers. The recent 50-gram siRNA contract ($1M+ value, 12-month delivery) exemplifies this model. Services revenue converts to larger supply agreements as customers advance through clinical stages.
Licensing Revenue: The Merck Technology Transfer Agreement generated $37.8M in Q4 2025. Codexis expects to sign additional licensing deals in 2026, potentially generating upfront fees, milestones, and royalties from partners who adopt ECO Synthesis for commercial manufacturing.
The business model is evolving from pure enzyme sales to a platform licensing and manufacturing services model with higher margins and recurring revenue potential.
Financial Highlights
Q4 2025 Results vs. Consensus
| Reported | Consensus | Beat | |
|---|---|---|---|
| Revenue | $38.9M | $35.8M | +8.7% |
| GAAP EPS | $0.11 | -$0.03 | +$0.14 |
| Product Gross Margin | 64% | 60%* | +400bps |
*Estimate
Full-Year FY2025 Results
| Metric | FY2025 | FY2024 | YoY% |
|---|---|---|---|
| Revenue | $70.4M | $59.3M | +18.7% |
| Q4 Revenue | $38.9M | $21.5M | +81.3% |
| Product Gross Margin | 64% | 56% | +800bps |
| R&D Expenses | $52.3M | $46.3M | +13.0% |
| SG&A Expenses | $47.1M | $55.1M | -14.5% |
| Net Income (Q4) | $9.6M | -$10.4M | +$20M |
| Net Loss (FY) | -$44.0M | -$65.3M | +33% improvement |
Balance Sheet & Cash Position
| Item | Amount |
|---|---|
| Cash & Short-Term Investments | $78.2M |
| Total Debt | Minimal |
| Cash Runway | Through 2027 |
| Market Cap (Pre-Market) | ~$120M |
| Shares Outstanding | ~63M |
2026 Guidance
- Revenue: $72M - $76M (midpoint $74M)
- Revenue weighted toward H2 2026
- Gross margins stable at ~64%
- Cash sufficient through 2027
Competitive Landscape
Codexis competes in the oligonucleotide manufacturing space, which is dominated by traditional solid-phase chemical synthesis. The company's ECO Synthesis platform is attempting to disrupt this market with enzymatic processes that offer scalability, cost, and quality advantages.
Key Competitors:
- Ionis Pharmaceuticals (IONS): Leader in antisense oligonucleotide therapeutics with internal manufacturing capabilities. Developing competing siRNA programs.
- Alnylam Pharmaceuticals (ALNY): Dominant player in siRNA therapeutics with four approved drugs. Uses traditional chemical synthesis with proprietary delivery technology.
- Sarepta Therapeutics (SRPT): PMO (phosphorodiamidate morpholino oligomer) manufacturer for Duchenne muscular dystrophy. Different chemistry but competing for oligonucleotide manufacturing capacity.
- CDMOs (Bachem, Nitto Avecia, Lonza): Contract manufacturers that currently use traditional synthesis methods. Codexis has partnered with three of these (Bachem, Nitto Avecia, Axolabs) to potentially adopt ECO Synthesis.
Codexis Moats:
- Proprietary Enzyme Technology: The CodeEvolver platform has generated a library of biocatalytic enzymes that are difficult to replicate.
- First-Mover in Enzymatic siRNA Synthesis: ECO Synthesis is the first scalable enzymatic process for siRNA manufacturing, giving Codexis a 2-3 year head start.
- CDMO Partnerships: Three signed agreements with major CDMOs provide distribution scale and validation.
- ISO 9001 + GMP Facility: Quality certifications and planned GMP production capability (2027) position Codexis for clinical and commercial supply.
Catalysts
- Scale-up to half-kilogram siRNA production by end of 2026 would validate commercial viability and enable larger contracts
- GMP facility retrofit begins H2 2026; operational by end of 2027 enables clinical and commercial GMP supply
- Additional licensing deals expected in 2026 (management stated intention to sign one) could provide non-dilutive capital
- Stereoisomer control data presentation at TIDES U.S. could demonstrate differentiated therapeutic potential
- Customer advancement from preclinical to IND/clinical stages triggers larger multi-year supply agreements
Key Risks
- Scale-up execution risk: moving from 100-gram to kilogram-scale production may encounter technical challenges
- Biotech funding environment: customer dependency on venture capital could delay or cancel programs
- Competition from larger players with deeper resources may develop competing enzymatic synthesis platforms
- Cash burn uncertainty: GMP facility build-out could exceed budget if construction delays occur
- Customer concentration: heavy reliance on small number of biotech customers for near-term revenue visibility
Our Thesis
Codexis has successfully pivoted from a struggling small-molecule biocatalysis company to a focused RNA manufacturing platform play. The ECO Synthesis technology uses enzymatic processes to synthesize siRNA therapeutics at scale, addressing the fundamental bottleneck in the oligonucleotide market: current solid-phase chemical synthesis can't keep up with demand. Industry estimates suggest 10-30 metric tons of oligonucleotide material will be needed by 2030. Codexis aims to be a key technology provider.
The commercial traction is real. Three CDMO agreements signed in 2025 exceeded management's target of one. A 55-opportunity pipeline across 40 companies demonstrates industry interest. The recent 50-gram siRNA contract with an emerging biotech (low 7-figures, split between services and product) provides a template for larger deals. If successful, this customer could move into clinical studies using ECO Synthesis, generating licensing fees, milestones, and commercial supply revenue. Management is targeting kilo-scale production by year-end 2026 with a GMP facility operational by 2027.
Valuation is reasonable for a platform company with validated technology and cash runway. At $1.89, Codexis trades at ~2.5x 2026 revenue guidance midpoint ($74M). For comparison, larger CDMOs trade at 4-6x revenue. Our $3.00 price target implies ~4x 2026 revenue, justified by platform optionality and the $2B TAM. Risks include execution on scale-up, competition from larger players, and dependency on biotech funding cycles.
Get reports like this delivered free
New small-cap research every week. No paywall, no fluff.